BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
back to Directory

GigaCeuticals

GigaCeuticals logo

Website
https://www.gigaceuticals.com/
Founded
2018
Patents
1
Publications
4

Technologies

AI Companies (Drug Discovery) Aging Research Pharmaceutical and Drug Discovery

Based on artificial intelligence technology, we independently developed an algorithm system with deep learning ability. We established a biological process model based on the experimental data and molecular data, and the model can help us analyze and predict the functions of all kinds of compounds and related properties of the compounds, and screen the target molecules, design and optimize specific functional compounds, predict drug toxicity and long-term side effects. The predicted results can be verified directly by mouse experiments, providing clinical trial drug candidates for drug developing companies.

deep learning

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

InfinityBind:AI Design Platform
The small molecule-target binding model established in the whole compound space is the key to accurately predict the possibility of the combination between any two small molecules and is the basic requirement for training an artificial intelligence agent for de-novo drug design using deep reinforcement learning. Based on a large dataset containing millions of records describing binding abilities between different compounds, InfinityBind successfully depicts the effective spatial information of the compounds’ targets using self-developed IMBalance Counter (IMBC) algorithm, which can be implemented to train a deep neural network using extremely unbalanced data. So far, we have accurately predicted hundreds of results about binding abilities between small molecules and their targets, and completed the molecular de-novo design based on deep reinforcement learning.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.